Wyeth Articles
Attack on US pharma "smokescreen"
18 August 2003
Altana on track as field force spend increases
11 August 2003
FDA clears expanded use of Enbrel
11 August 2003
Divestments boost Wyeth as profits soar
4 August 2003
Enbrel gets FDA OK for expanded use
4 August 2003
Wyeth's low-dose Prempro launched
7 July 2003
Stock Commentary - New York
30 June 2003
French drug industry body names new board members
30 June 2003
Wyeth's Enbrel effective in AS
30 June 2003
Wyeth's Enbrel effective in AS
30 June 2003
FDA OKs MedImmune and Wyeth's FluMist
30 June 2003
Stock Commentary - New York
23 June 2003
Barr completes deal to acquire Wyeth prods
16 June 2003
FDA approves Wyeth's low-dose Prempro
16 June 2003
Lupin to launch cefixime in USA
16 June 2003
Biovail in $130M rights deal with Wyeth
9 June 2003
Crestor advisory panel raises fears of delay
26 May 2003
Takeda/Wyeth abandon JV
26 May 2003
Zealand gap junction drug licensed to Wyeth
12 May 2003
US sales boost 1st-qtr profits at Altana
12 May 2003
Stock Commentary - New York
5 May 2003
Colorado Medicaid sets eight-drug limit
5 May 2003
Wyeth's Zosyn dosing cut
5 May 2003
US FDA "has authority for Rx-OTC switches"
5 May 2003
Profits up at Wyeth, HRT sales still suffering
28 April 2003
Profits up at Australia's Sigma on Wyeth brand sales
28 April 2003
Rapamune gets new indication from FDA
21 April 2003
Medtronik/Wyeth's rhBMP-2 device cleared in Canada
14 April 2003
FDA OKs Wyeth's low-dose Prempro
24 March 2003
Pharma insurance liability premiums soar
24 March 2003
Prempro may worsen cognition; new study
10 March 2003
Stock Commentary - New York
10 March 2003
Wyeth licensed Oxford Bio antibody in $24M deal
10 March 2003
Effexor cleared for social phobia in USA
17 February 2003
High US co-pays "are driving PPI switches"
17 February 2003
Stock Commentary - New York
10 February 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
Sepracor seeks US OK for eszopiclone
10 February 2003
Impax' generic Claritin cleared in USA
10 February 2003
Pharmaceutical blockbusters; new marketing guide
10 February 2003
Wyeth licenses VSV patents to GTx
3 February 2003
European court overturns obesity drug ban
3 February 2003
Earnings up at Wyeth, HRT drugs sluggish
3 February 2003
Looming Claritin rivals cut S-P shares 7%
3 February 2003
Claritin switch hits S-P, sales down 4% in 2002
3 February 2003
Altana AG sees 2002 sales grow 13%
3 February 2003
Wyeth faces allegations of tax evasion
27 January 2003
US court overturns $226 million Wyeth tax refund
20 January 2003
Japan's drugmakers face growing rivalry
20 January 2003
S-P lowers forecast as Claritin rivalry bites
20 January 2003
US FDA tells women:
20 January 2003
Round-up of pharmaceutical mergers and acquisitions during 2001
13 January 2003
Wyeth, Abbott accused over "false" prices
13 January 2003
Update - Wyeth gets final OTC Claritin approval
6 January 2003
Wyeth gets final OTC Claritin approval
6 January 2003
Baxter acquires ESI in $305M deal
6 January 2003
Stock Commentary - New York
19 August 2002
Wyeth's American Cyanamid ordered to pay $54.1M by judge
19 August 2002
ZymoGenetics net loss up 55% in 2nd qtr
19 August 2002
Stock Commentary - New York
12 August 2002
Stock Commentary - New York
5 August 2002
ZymoGenetics sign licensing accord with Wyeth
5 August 2002
Wyeth EPS increases 25% during 2nd qtr
29 July 2002
Stock Commentary - New York
29 July 2002
Stock Commentary - Europe
29 July 2002
Additional trial finds elevated risk with HRT
22 July 2002
Stock Commentary - New York
22 July 2002
Stock Commentary - Europe
22 July 2002
Karo Bio 2nd-qtr losses down by 7%
22 July 2002
Wyeth gets OK to use Celsis' microbial system
22 July 2002
Prempro fall-out could affect Schering AG
22 July 2002
Wyeth hit as Prempro linked to cancer, CVD
15 July 2002
Octapharma to buy Biovitrum plasma unit
8 July 2002
Wyeth's bazedoxifene on market by 2006?
8 July 2002
Impax and Wyeth in OTC collaboration
1 July 2002
AARP consumer hot-line for anti-generics suits
24 June 2002
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
